ffntf-20230930000178387512/312023Q3falseP9M500.083300017838752023-01-012023-09-300001783875ffntf:ClassASubordinateVotingShareMember2023-01-012023-09-300001783875dei:AdrMember2023-01-012023-09-3000017838752023-11-20xbrli:shares00017838752023-09-30iso4217:USD00017838752022-12-3100017838752023-07-012023-09-3000017838752022-07-012022-09-3000017838752022-01-012022-09-30iso4217:USDxbrli:shares0001783875us-gaap:CapitalUnitsMember2022-12-310001783875us-gaap:AdditionalPaidInCapitalMember2022-12-310001783875us-gaap:RetainedEarningsMember2022-12-310001783875us-gaap:ParentMember2022-12-310001783875us-gaap:NoncontrollingInterestMember2022-12-310001783875us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001783875us-gaap:ParentMember2023-01-012023-03-3100017838752023-01-012023-03-310001783875us-gaap:RetainedEarningsMember2023-01-012023-03-310001783875us-gaap:NoncontrollingInterestMember2023-01-012023-03-310001783875us-gaap:CapitalUnitsMember2023-03-310001783875us-gaap:AdditionalPaidInCapitalMember2023-03-310001783875us-gaap:RetainedEarningsMember2023-03-310001783875us-gaap:ParentMember2023-03-310001783875us-gaap:NoncontrollingInterestMember2023-03-3100017838752023-03-310001783875us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001783875us-gaap:ParentMember2023-04-012023-06-3000017838752023-04-012023-06-300001783875us-gaap:CapitalUnitsMember2023-04-012023-06-300001783875us-gaap:RetainedEarningsMember2023-04-012023-06-300001783875us-gaap:NoncontrollingInterestMember2023-04-012023-06-300001783875us-gaap:CapitalUnitsMember2023-06-300001783875us-gaap:AdditionalPaidInCapitalMember2023-06-300001783875us-gaap:RetainedEarningsMember2023-06-300001783875us-gaap:ParentMember2023-06-300001783875us-gaap:NoncontrollingInterestMember2023-06-3000017838752023-06-300001783875us-gaap:CapitalUnitsMember2023-07-012023-09-300001783875us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001783875us-gaap:ParentMember2023-07-012023-09-300001783875us-gaap:RetainedEarningsMember2023-07-012023-09-300001783875us-gaap:NoncontrollingInterestMember2023-07-012023-09-300001783875us-gaap:CapitalUnitsMember2023-09-300001783875us-gaap:AdditionalPaidInCapitalMember2023-09-300001783875us-gaap:RetainedEarningsMember2023-09-300001783875us-gaap:ParentMember2023-09-300001783875us-gaap:NoncontrollingInterestMember2023-09-300001783875us-gaap:CapitalUnitsMember2021-12-310001783875us-gaap:AdditionalPaidInCapitalMember2021-12-310001783875us-gaap:RetainedEarningsMember2021-12-310001783875us-gaap:ParentMember2021-12-310001783875us-gaap:NoncontrollingInterestMember2021-12-3100017838752021-12-310001783875ffntf:NewEnglandCannabisCorporationIncMemberus-gaap:CapitalUnitsMember2022-01-012022-03-310001783875ffntf:NewEnglandCannabisCorporationIncMemberus-gaap:ParentMember2022-01-012022-03-310001783875ffntf:NewEnglandCannabisCorporationIncMember2022-01-012022-03-310001783875us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001783875us-gaap:ParentMember2022-01-012022-03-3100017838752022-01-012022-03-310001783875us-gaap:CapitalUnitsMember2022-01-012022-03-310001783875us-gaap:RetainedEarningsMember2022-01-012022-03-310001783875us-gaap:NoncontrollingInterestMember2022-01-012022-03-310001783875us-gaap:CapitalUnitsMember2022-03-310001783875us-gaap:AdditionalPaidInCapitalMember2022-03-310001783875us-gaap:RetainedEarningsMember2022-03-310001783875us-gaap:ParentMember2022-03-310001783875us-gaap:NoncontrollingInterestMember2022-03-3100017838752022-03-310001783875us-gaap:CapitalUnitsMemberffntf:IslandGlobalHoldingsInc.Member2022-04-012022-06-300001783875ffntf:IslandGlobalHoldingsInc.Memberus-gaap:ParentMember2022-04-012022-06-300001783875ffntf:IslandGlobalHoldingsInc.Member2022-04-012022-06-300001783875us-gaap:CapitalUnitsMember2022-04-012022-06-300001783875us-gaap:ParentMember2022-04-012022-06-3000017838752022-04-012022-06-300001783875us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001783875us-gaap:RetainedEarningsMember2022-04-012022-06-300001783875us-gaap:NoncontrollingInterestMember2022-04-012022-06-300001783875us-gaap:CapitalUnitsMember2022-06-300001783875us-gaap:AdditionalPaidInCapitalMember2022-06-300001783875us-gaap:RetainedEarningsMember2022-06-300001783875us-gaap:ParentMember2022-06-300001783875us-gaap:NoncontrollingInterestMember2022-06-3000017838752022-06-300001783875us-gaap:CapitalUnitsMemberffntf:BloomMember2022-07-012022-09-300001783875us-gaap:ParentMemberffntf:BloomMember2022-07-012022-09-300001783875ffntf:BloomMember2022-07-012022-09-300001783875us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001783875us-gaap:ParentMember2022-07-012022-09-300001783875us-gaap:RetainedEarningsMember2022-07-012022-09-300001783875us-gaap:NoncontrollingInterestMember2022-07-012022-09-300001783875us-gaap:CapitalUnitsMember2022-09-300001783875us-gaap:AdditionalPaidInCapitalMember2022-09-300001783875us-gaap:RetainedEarningsMember2022-09-300001783875us-gaap:ParentMember2022-09-300001783875us-gaap:NoncontrollingInterestMember2022-09-3000017838752022-09-30ffntf:Segment0001783875ffntf:THCCannabisSegmentMember2023-01-012023-09-30ffntf:Dispensaryffntf:facility0001783875ffntf:UnharvestedCannabisMember2023-09-300001783875ffntf:UnharvestedCannabisMember2022-12-310001783875ffntf:HarvestedAndPurchasedCannabisMember2023-09-300001783875ffntf:HarvestedAndPurchasedCannabisMember2022-12-310001783875us-gaap:LandMember2023-09-300001783875us-gaap:LandMember2022-12-310001783875us-gaap:BuildingAndBuildingImprovementsMember2023-09-300001783875us-gaap:BuildingAndBuildingImprovementsMember2022-12-310001783875us-gaap:ConstructionInProgressMember2023-09-300001783875us-gaap:ConstructionInProgressMember2022-12-310001783875ffntf:FurnitureEquipmentAndOtherMember2023-09-300001783875ffntf:FurnitureEquipmentAndOtherMember2022-12-310001783875us-gaap:LeaseholdImprovementsMember2023-09-300001783875us-gaap:LeaseholdImprovementsMember2022-12-310001783875ffntf:ILGrownMedicineLLCMembersrt:MinimumMember2022-10-270001783875ffntf:ILGrownMedicineLLCMembersrt:MaximumMember2022-10-270001783875ffntf:ILGrownMedicineLLCMember2022-11-102022-11-100001783875ffntf:ILGrownMedicineLLCMember2022-11-100001783875us-gaap:LicensingAgreementsMember2022-12-310001783875us-gaap:CustomerRelationshipsMember2022-12-310001783875us-gaap:NoncompeteAgreementsMember2022-12-310001783875us-gaap:TradeSecretsMember2022-12-310001783875us-gaap:TrademarksAndTradeNamesMember2022-12-310001783875us-gaap:LicensingAgreementsMember2023-01-012023-09-300001783875us-gaap:CustomerRelationshipsMember2023-01-012023-09-300001783875us-gaap:NoncompeteAgreementsMember2023-01-012023-09-300001783875us-gaap:TradeSecretsMember2023-01-012023-09-300001783875us-gaap:TrademarksAndTradeNamesMember2023-01-012023-09-300001783875us-gaap:LicensingAgreementsMember2023-09-300001783875us-gaap:CustomerRelationshipsMember2023-09-300001783875us-gaap:NoncompeteAgreementsMember2023-09-300001783875us-gaap:TradeSecretsMember2023-09-300001783875us-gaap:TrademarksAndTradeNamesMember2023-09-300001783875ffntf:THCCannabisSegmentMember2023-09-300001783875ffntf:CBDWellnessSegmentMember2023-09-300001783875ffntf:EuphoriaLLCMember2023-03-27xbrli:pure0001783875ffntf:EuphoriaLLCMember2023-03-272023-03-270001783875ffntf:EuphoriaLLCMember2023-03-282023-09-300001783875ffntf:WarrantsExercisableThroughMay12026Member2023-08-100001783875ffntf:FirstAmendmentToLILendingLLCLoanAgreementMember2023-08-102023-08-100001783875ffntf:DebtInstrumentRefinanceTermOneMember2023-08-100001783875ffntf:DebtInstrumentRefinanceTermOneMemberffntf:WarrantsExercisableThroughMay12026Member2023-08-100001783875ffntf:DebtInstrumentRefinanceTermTwoMember2023-08-100001783875ffntf:DebtInstrumentRefinanceTermTwoMemberffntf:WarrantsExercisableThroughMay12026Member2023-08-100001783875us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2022-11-300001783875us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2023-09-300001783875us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember2022-11-300001783875us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember2023-09-300001783875us-gaap:MeasurementInputExpectedTermMemberus-gaap:FairValueInputsLevel3Member2022-11-30utr:Y0001783875us-gaap:MeasurementInputExpectedTermMemberus-gaap:FairValueInputsLevel3Member2023-09-300001783875us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2022-11-300001783875us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2023-09-300001783875us-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:FairValueInputsLevel3Member2022-11-300001783875us-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:FairValueInputsLevel3Member2023-09-300001783875ffntf:WarrantLiabilitiesMember2023-06-300001783875ffntf:WarrantLiabilitiesMember2022-06-300001783875ffntf:WarrantLiabilitiesMember2022-12-310001783875ffntf:WarrantLiabilitiesMember2021-12-310001783875ffntf:WarrantLiabilitiesMember2023-07-012023-09-300001783875ffntf:WarrantLiabilitiesMember2022-07-012022-09-300001783875ffntf:WarrantLiabilitiesMember2023-01-012023-09-300001783875ffntf:WarrantLiabilitiesMember2022-01-012022-09-300001783875ffntf:WarrantLiabilitiesMember2023-09-300001783875ffntf:WarrantLiabilitiesMember2022-09-300001783875ffntf:LeaseAgreementForTheThirdDispensaryLocationInIllinoisMember2023-08-232023-08-230001783875ffntf:LeaseAgreementForTheThirdDispensaryLocationInIllinoisMember2023-09-300001783875ffntf:LeaseAgreementForCultivationAndProductionFacilityInMattesonIllinoisMember2023-07-070001783875us-gaap:BuildingMember2023-09-300001783875us-gaap:BuildingMember2022-12-3100017838752022-01-012022-12-3100017838752023-07-070001783875ffntf:InterestRatePeriodOneMemberffntf:SecuredPromissoryNoteDatedMay102019Member2023-09-300001783875ffntf:InterestRatePeriodTwoMemberffntf:SecuredPromissoryNoteDatedMay102019Member2023-09-300001783875ffntf:SecuredPromissoryNoteDatedMay102019Member2023-09-300001783875ffntf:SecuredPromissoryNoteDatedMay102019Member2022-12-310001783875ffntf:ConvertiblePromissoryNoteDatedOctober62021Member2023-09-300001783875ffntf:ConvertiblePromissoryNoteDatedOctober62021Member2022-12-310001783875ffntf:UnsecuredConvertiblePromissoryNoteAt050PerShareDueDecember182023Member2023-09-300001783875ffntf:InterestRatePeriodOneMemberffntf:UnsecuredConvertiblePromissoryNoteAt050PerShareDueDecember182023Member2023-09-300001783875ffntf:InterestRatePeriodTwoMemberffntf:UnsecuredConvertiblePromissoryNoteAt050PerShareDueDecember182023Member2023-09-300001783875ffntf:UnsecuredConvertiblePromissoryNoteAt050PerShareDueDecember182023Member2022-12-310001783875ffntf:PromissoryNoteIssuedForNECCAcquisitionMember2023-09-300001783875ffntf:PromissoryNoteIssuedForNECCAcquisitionMember2022-12-310001783875ffntf:PromissoryNoteIssuedForIslandAcquisitionMember2023-09-300001783875ffntf:PromissoryNoteIssuedForIslandAcquisitionMember2022-12-310001783875ffntf:InterestRatePeriodOneMemberffntf:SecuredPromissoryNoteDueFebruary282023Member2023-09-300001783875ffntf:InterestRatePeriodTwoMemberffntf:SecuredPromissoryNoteDueFebruary282023Member2023-09-300001783875ffntf:SecuredPromissoryNoteDueFebruary282023Member2023-09-300001783875ffntf:SecuredPromissoryNoteDueFebruary282023Member2022-12-310001783875ffntf:InterestRatePeriodOneMemberffntf:UnsecuredPromissoryNoteDueNovember302024Member2023-09-300001783875ffntf:InterestRatePeriodTwoMemberffntf:UnsecuredPromissoryNoteDueNovember302024Member2023-09-300001783875ffntf:UnsecuredPromissoryNoteDueNovember302024Member2023-09-300001783875ffntf:UnsecuredPromissoryNoteDueNovember302024Member2022-12-310001783875ffntf:VariousMember2023-09-300001783875ffntf:VariousMember2022-12-310001783875ffntf:SecuredPromissoryNoteDueFebruary282023Member2023-01-012023-09-300001783875ffntf:LILendingLLCLoanAgreementMember2019-05-100001783875ffntf:LILendingLLCLoanAgreementMember2023-09-30ffntf:draw0001783875ffntf:LILendingFacilityDrawOneMemberffntf:LILendingLLCLoanAgreementMember2023-09-300001783875ffntf:LILendingLLCLoanAgreementMemberffntf:LILendingFacilityDrawTwoMember2023-09-300001783875ffntf:LILendingLLCLoanAgreementMember2023-01-012023-09-300001783875ffntf:LILendingFacilityDrawOneMemberffntf:LILendingLLCLoanAgreementMember2020-04-302020-04-300001783875ffntf:LILendingFacilityDrawOneMemberffntf:LILendingLLCLoanAgreementMember2020-04-300001783875ffntf:LILendingLLCLoanAgreementMember2020-12-012020-12-310001783875ffntf:LILendingFacilityDrawOneMemberffntf:LILendingLLCLoanAgreementMember2022-01-010001783875ffntf:LILendingLLCLoanAgreementMemberffntf:LILendingFacilityDrawTwoMember2022-01-010001783875ffntf:FirstAmendmentToLILendingLLCLoanAgreementMember2023-07-310001783875ffntf:FirstAmendmentToLILendingLLCLoanAgreementMember2023-07-012023-07-310001783875ffntf:FirstAmendmentToLILendingLLCLoanAgreementMember2023-07-012023-09-300001783875ffntf:LILendingLLCLoanAgreementMember2023-07-012023-09-300001783875ffntf:LILendingLLCLoanAgreementMember2022-07-012022-09-300001783875ffntf:LILendingLLCLoanAgreementMember2022-01-012022-09-300001783875ffntf:OctoberTwoThousandAndTwentyOneConvertibleNoteMemberus-gaap:ConvertibleDebtMember2021-10-060001783875ffntf:OctoberTwoThousandAndTwentyOneConvertibleNoteMemberus-gaap:ConvertibleDebtMember2023-01-012023-09-300001783875ffntf:OctoberTwoThousandAndTwentyOneConvertibleNoteMemberus-gaap:ConvertibleDebtMember2023-09-300001783875ffntf:OctoberTwoThousandAndTwentyOneConvertibleNoteMemberus-gaap:ConvertibleDebtMember2022-12-310001783875ffntf:OctoberTwoThousandAndTwentyOneConvertibleNoteMemberus-gaap:ConvertibleDebtMember2022-01-012022-09-300001783875ffntf:ClassASubordinateVotingSharesMember2022-12-310001783875ffntf:ClassCMultipleVotingSharesMember2022-12-310001783875ffntf:ClassASubordinateVotingSharesMember2023-01-012023-09-300001783875ffntf:ClassCMultipleVotingSharesMember2023-01-012023-09-300001783875ffntf:ClassASubordinateVotingSharesMember2023-09-300001783875ffntf:ClassCMultipleVotingSharesMember2023-09-30ffntf:vote0001783875us-gaap:CommonClassAMember2023-09-300001783875us-gaap:CommonClassCMember2023-09-300001783875ffntf:WarrantExercisePriceOneMember2023-09-300001783875ffntf:WarrantExercisePriceZeroPointEightZeroMember2023-09-30iso4217:CADxbrli:shares0001783875ffntf:WarrantExercisePriceZeroPointEightZero2Member2023-09-300001783875ffntf:WarrantExercisePriceZeroPointTwoThreeMember2023-09-300001783875ffntf:WarrantExercisePriceZeroPointOneZeroMember2023-09-30ffntf:plan0001783875ffntf:EquityIncentivePlanMemberffntf:ClassAStockOptionsMember2023-01-012023-09-300001783875srt:MinimumMember2023-09-300001783875srt:MaximumMember2023-09-300001783875ffntf:EquityIncentivePlanMember2023-07-012023-09-300001783875ffntf:EquityIncentivePlanMember2022-07-012022-09-300001783875ffntf:EquityIncentivePlanMember2023-01-012023-09-300001783875ffntf:EquityIncentivePlanMember2022-01-012022-09-300001783875us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001783875us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001783875us-gaap:RestrictedStockUnitsRSUMember2023-07-272023-07-270001783875us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001783875us-gaap:RelatedPartyMemberffntf:SecuredPromissoryNoteDatedMay102019Member2019-05-100001783875us-gaap:RelatedPartyMemberffntf:SecuredPromissoryNoteDatedMay102019Member2023-09-300001783875us-gaap:RelatedPartyMembersrt:ChiefExecutiveOfficerMemberffntf:LILendingLLCMember2023-09-300001783875srt:DirectorMemberus-gaap:RelatedPartyMemberffntf:LILendingLLCMember2023-09-300001783875us-gaap:RelatedPartyMemberffntf:FirstAmendmentToLILendingLLCLoanAgreementMember2023-07-012023-07-310001783875us-gaap:RelatedPartyMemberffntf:FirstAmendmentToLILendingLLCLoanAgreementMember2023-07-3100017838752022-01-262022-01-2600017838752022-09-122022-09-1200017838752022-09-12ffntf:installment0001783875ffntf:LitigationSuedByFlorivalMember2023-05-092023-05-090001783875ffntf:LitigationSuedByFlorivalMember2023-09-300001783875ffntf:LitigationSuedByTeichmanSeptember142023Member2023-09-142023-09-140001783875ffntf:LitigationSuedByTeichmanSeptember142023Member2023-09-300001783875ffntf:LitigationSuedByTeichmanSeptember292023Member2023-09-292023-09-290001783875ffntf:LitigationSuedByTeichmanSeptember292023Member2023-09-290001783875ffntf:LitigationSuedByTeichmanSeptember292023Member2023-09-300001783875us-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-09-300001783875ffntf:ConvertibleNotesNotesPayableAndAccruedInterestMember2023-09-300001783875ffntf:ConstructionFinanceLiabilityMember2023-09-300001783875us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMemberffntf:CaliforniaOperationsMember2023-07-012023-09-300001783875us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMemberffntf:CaliforniaOperationsMember2023-01-012023-09-300001783875us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMemberffntf:CaliforniaOperationsMember2023-09-300001783875us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMemberffntf:CaliforniaOperationsMember2022-07-012022-09-300001783875us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMemberffntf:CaliforniaOperationsMember2022-01-012022-09-300001783875us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMemberffntf:CaliforniaOperationsMember2022-12-310001783875ffntf:THCCannabisSegmentMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300001783875ffntf:THCCannabisSegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300001783875ffntf:THCCannabisSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300001783875ffntf:THCCannabisSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300001783875us-gaap:OperatingSegmentsMemberffntf:CBDWellnessSegmentMember2023-07-012023-09-300001783875us-gaap:OperatingSegmentsMemberffntf:CBDWellnessSegmentMember2022-07-012022-09-300001783875us-gaap:OperatingSegmentsMemberffntf:CBDWellnessSegmentMember2023-01-012023-09-300001783875us-gaap:OperatingSegmentsMemberffntf:CBDWellnessSegmentMember2022-01-012022-09-300001783875us-gaap:CorporateNonSegmentMember2023-07-012023-09-300001783875us-gaap:CorporateNonSegmentMember2022-07-012022-09-300001783875us-gaap:CorporateNonSegmentMember2023-01-012023-09-300001783875us-gaap:CorporateNonSegmentMember2022-01-012022-09-300001783875ffntf:THCCannabisSegmentMemberus-gaap:OperatingSegmentsMember2023-09-300001783875ffntf:THCCannabisSegmentMemberus-gaap:OperatingSegmentsMember2022-12-310001783875us-gaap:OperatingSegmentsMemberffntf:CBDWellnessSegmentMember2023-09-300001783875us-gaap:OperatingSegmentsMemberffntf:CBDWellnessSegmentMember2022-12-310001783875us-gaap:CorporateNonSegmentMember2023-09-300001783875us-gaap:CorporateNonSegmentMember2022-12-310001783875ffntf:UnsecuredConvertiblePromissoryNoteWithHealthyPharmsIncMemberus-gaap:UnsecuredDebtMemberus-gaap:SubsequentEventMember2023-10-020001783875ffntf:UnsecuredConvertiblePromissoryNoteWithHealthyPharmsIncMemberus-gaap:UnsecuredDebtMemberus-gaap:SubsequentEventMember2023-10-022023-10-020001783875ffntf:UnsecuredConvertiblePromissoryNoteWithHealthyPharmsIncMemberus-gaap:UnsecuredDebtMemberus-gaap:SubsequentEventMember2023-11-012023-11-200001783875ffntf:OctoberTwoThousandAndTwentyOneConvertibleNoteMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember2023-10-060001783875ffntf:PromissoryNotePurchaseAgreementWithHI4FrontLLCAndNavyCapitalGreenFundLPMemberus-gaap:SubsequentEventMember2023-10-102023-10-10iso4217:CAD0001783875ffntf:WarrantsForExtensionFeeMemberffntf:PromissoryNotePurchaseAgreementWithHI4FrontLLCAndNavyCapitalGreenFundLPMemberus-gaap:SubsequentEventMember2023-10-100001783875ffntf:SeniorSecuredCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2023-10-130001783875ffntf:SeniorSecuredCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2023-10-132023-10-130001783875ffntf:SeniorSecuredCreditFacilityMemberus-gaap:PrimeRateMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2023-10-132023-10-130001783875us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SubsequentEventMember2023-11-132023-11-130001783875us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SubsequentEventMember2023-11-130001783875ffntf:MichiganDispensaryLocationMemberus-gaap:DisposalGroupNotDiscontinuedOperationsMember2023-01-012023-09-300001783875us-gaap:SubsequentEventMember2023-11-172023-11-170001783875us-gaap:SubsequentEventMember2023-11-170001783875ffntf:WestsideMemberus-gaap:SubsequentEventMember2023-11-170001783875ffntf:WestsideMemberus-gaap:SubsequentEventMember2023-11-172023-11-17
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: September 30, 2023
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______________ to ______________
Commission File Number 000-56075
4Front Ventures Corp.
(Exact name of registrant as specified in its charter)
| | | | | | | | |
British Columbia | | 83-4168417 |
(State or other jurisdiction of incorporation or organization) | | (IRS Employer Identification No.) |
7010 E. Chauncey Lane
Suite 235
Phoenix, Arizona 85054
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (602) 633-3067
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
Title of Each Class | | Trading Symbol(s) | | Name of Each Exchange on Which Registered |
Class A Subordinate Voting Shares, no par value | | FFNTF | | OTCQX |
| | FFNT | | CSE |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
| | | | | |
Large accelerated filer ☐ | Accelerated filer ☐ |
Non-accelerated filer ☒ | Smaller reporting company ☒ |
| Emerging growth company ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 20, 2023, the registrant had 668,243,141 Class A Subordinate Voting Shares outstanding.
4Front Ventures Corp.
FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023
TABLE OF CONTENTS
| | | | | | | | |
| | Page |
PART I. | FINANCIAL INFORMATION | |
| | |
| Consolidated Financial Statements (unaudited) | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
PART II. | OTHER INFORMATION | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (unaudited)
As of September 30, 2023 and December 31, 2022
(Amounts expressed in thousands of U.S. dollars except for share data)
| | | | | | | | | | | | | | |
| | September 30, 2023 | | December 31, 2022 |
ASSETS | | | | |
Current assets: | | | | |
Cash | | $ | 2,765 | | | $ | 14,271 | |
Accounts receivable, net | | 4,208 | | | 5,448 | |
Other receivables | | 222 | | | 93 | |
Current portion of lease receivables | | 3,945 | | | 3,810 | |
Inventory | | 17,162 | | | 18,888 | |
| | | | |
| | | | |
Prepaid expenses and other assets | | 2,536 | | | 1,015 | |
Assets related to discontinued operations | | 2,918 | | | 9,742 | |
Total current assets | | 33,756 | | | 53,267 | |
Property, plant, and equipment, net | | 39,286 | | | 34,414 | |
| | | | |
Lease receivables | | 4,436 | | | 5,611 | |
Intangible assets, net | | 27,351 | | | 29,240 | |
Goodwill | | 41,807 | | | 41,807 | |
Right-of-use assets | | 120,219 | | | 121,929 | |
Deposits | | 2,419 | | | 4,996 | |
Long term assets related to discontinued operations | | — | | | 53,468 | |
TOTAL ASSETS | | $ | 269,274 | | | $ | 344,732 | |
LIABILITIES AND SHAREHOLDERS' EQUITY | | | | |
LIABILITIES | | | | |
Current liabilities: | | | | |
Accounts payable | | $ | 12,305 | | | $ | 11,101 | |
Accrued expenses and other current liabilities | | 8,958 | | | 9,101 | |
Taxes payable | | 38,539 | | | 36,577 | |
Derivative liability | | 16,096 | | | — | |
| | | | |
| | | | |
Current portion of lease liability | | 1,990 | | | 2,767 | |
| | | | |
Current portion of notes payable and accrued interest | | 8,248 | | | 9,059 | |
Current liabilities related to discontinued operations | | 11,807 | | | 8,845 | |
Total current liabilities | | 97,943 | | | 77,450 | |
Convertible notes | | 15,677 | | | 14,843 | |
Notes payable and accrued interest from related party | | 46,827 | | | 49,807 | |
Long term notes payable | | 10,908 | | | 10,456 | |
Long term accounts payable | | 977 | | | 962 | |
| | | | |
| | | | |
Construction finance liability | | 16,000 | | | 16,000 | |
Deferred tax liability | | 7,293 | | | 6,097 | |
Lease liability | | 124,241 | | | 120,672 | |
Long term liabilities related to discontinued operations | | — | | | 20,094 | |
TOTAL LIABILITIES | | 319,866 | | | 316,381 | |
SHAREHOLDERS' EQUITY (DEFICIT) | | | | |
Subordinate Voting Shares (no par value, unlimited shares authorized, 659,159,977 and 643,416,275 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively) | | 306,561 | | | 304,602 | |
Additional paid-in capital | | 63,461 | | | 59,411 | |
Deficit | | (420,722) | | | (335,755) | |
Equity attributable to 4Front Ventures Corp. | | (50,700) | | | 28,258 | |
Non-controlling interest | | 108 | | | 93 | |
TOTAL SHAREHOLDERS' EQUITY (DEFICIT) | | (50,592) | | | 28,351 | |
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) | | $ | 269,274 | | | $ | 344,732 | |
See accompanying notes to condensed consolidated interim financial statements.
1
4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS (unaudited)
For the Three and Nine Months Ended September 30, 2023 and 2022
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 30, | | Nine Months Ended September 30, |
| | 2023 | | 2022 | | 2023 | | 2022 |
REVENUE | | | | | | | | |
Revenue from sale of goods | | $ | 20,110 | | | $ | 25,035 | | | $ | 67,709 | | | $ | 70,847 | |
Real estate income | | 2,892 | | | 3,065 | | | 8,747 | | | 8,981 | |
Total revenues | | 23,002 | | | 28,100 | | | 76,456 | | | 79,828 | |
Cost of goods sold | | (13,722) | | | (11,039) | | | (38,884) | | | (35,680) | |
Gross profit | | 9,280 | | | 17,061 | | | 37,572 | | | 44,148 | |
OPERATING EXPENSES | | | | | | | | |
Selling, general and administrative expenses | | 18,729 | | | 12,938 | | | 44,511 | | | 35,371 | |
Depreciation and amortization | | 817 | | | 859 | | | 2,406 | | | 2,474 | |
Share-based compensation | | 3,678 | | | 863 | | | 4,912 | | | 2,291 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Transaction and restructuring related expenses | | 195 | | | 60 | | | 212 | | | 734 | |
Total operating expenses | | 23,419 | | | 14,720 | | | 52,041 | | | 40,870 | |
Income (loss) from continuing operations | | (14,139) | | | 2,341 | | | (14,469) | | | 3,278 | |
Other income (expense) | | | | | | | | |
Interest income | | (21) | | | 6 | | | — | | | 8 | |
Interest expense | | (3,322) | | | (3,642) | | | (9,561) | | | (9,066) | |
| | | | | | | | |
Change in fair value of derivative liability | | (11,931) | | | 420 | | | (11,931) | | | 3,494 | |
| | | | | | | | |
Loss on disposal | | (160) | | | — | | | (160) | | | — | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Gain on contingent consideration payable | | — | | | — | | | — | | | 2,393 | |
Loss on litigation settlement | | — | | | (250) | | | (3) | | | (250) | |
| | | | | | | | |
Other | | (1,054) | | | 456 | | | (2,621) | | | 352 | |
Total other expense, net | | (16,488) | | | (3,010) | | | (24,276) | | | (3,069) | |
Net income (loss) from continuing operations before income taxes | | (30,627) | | | (669) | | | (38,745) | | | 209 | |
Income tax benefit (expense) | | 4,199 | | | (3,321) | | | (818) | | | (9,801) | |
Net loss from continuing operations | | (26,428) | | | (3,990) | | | (39,563) | | | (9,592) | |
Net loss from discontinued operations, net of taxes | | (35,668) | | | (4,611) | | | (45,389) | | | (11,449) | |
Net loss | | (62,096) | | | (8,601) | | | (84,952) | | | (21,041) | |
Net income attributable to non-controlling interest | | 5 | | | 5 | | | 15 | | | 15 | |
Net loss attributable to shareholders | | $ | (62,101) | | | $ | (8,606) | | | $ | (84,967) | | | $ | (21,056) | |
Basic and diluted loss per share - continuing operations | | $ | (0.04) | | | $ | (0.01) | | | $ | (0.06) | | | $ | (0.02) | |
Basic and diluted loss per share - discontinued operations | | $ | (0.05) | | | $ | (0.01) | | | $ | (0.07) | | | $ | (0.02) | |
Weighted average number of shares outstanding, basic and diluted | | 653,080,343 | | | 639,624,851 | | | 647,329,688 | | | 632,048,250 | |
See accompanying notes to condensed consolidated interim financial statements.
2
4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) (unaudited)
For the Nine Months Ended September 30, 2023 and 2022
(Amounts expressed in thousands of U.S. dollars except for share data)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Share Capital | | | | | | | | | | |
| | Shares | | Amount | | Additional Paid-In Capital | | Deficit | | Total 4Front Ventures Corp. Shareholders' Equity (Deficit) | | Non-Controlling Interest | | Total Shareholders' Equity (Deficit) |
Balance, December 31, 2022 | | 643,416,275 | | | $ | 304,602 | | | $ | 59,411 | | | $ | (335,755) | | | $ | 28,258 | | | $ | 93 | | | $ | 28,351 | |
Share-based compensation | | — | | | — | | | 1,020 | | | — | | | 1,020 | | | — | | | 1,020 | |
Net loss | | — | | | — | | | — | | | (11,397) | | | (11,397) | | | 5 | | | (11,392) | |
Balance, March 31, 2023 | | 643,416,275 | | | $ | 304,602 | | | $ | 60,431 | | | $ | (347,152) | | | $ | 17,881 | | | $ | 98 | | | $ | 17,979 | |
Share-based compensation | | — | | | — | | | 214 | | | — | | | 214 | | | — | | | 214 | |
Shares issued for asset acquisition | | 2,380,952 | | | 447 | | | — | | | — | | | 447 | | | — | | | 447 | |
Shares issued to settle payables | | 4,062,500 | | | 650 | | | — | | | — | | | 650 | | | — | | | 650 | |
Net loss | | — | | | — | | | — | | | (11,469) | | | (11,469) | | | 5 | | | (11,464) | |
Balance, June 30, 2023 | | 649,859,727 | | | $ | 305,699 | | | $ | 60,645 | | | $ | (358,621) | | | $ | 7,723 | | | $ | 103 | | | $ | 7,826 | |
Share-based compensation | | — | | | — | | | 2,634 | | | — | | | 2,634 | | | — | | | 2,634 | |
Warrants issued | | — | | | — | | | 182 | | | — | | | 182 | | | — | | | 182 | |
Shares issued for executive compensation | | 9,300,250 | | | 862 | | | — | | | — | | | 862 | | | — | | | 862 | |
Net loss | | — | | | — | | | — | | | (62,101) | | | (62,101) | | | 5 | | | (62,096) | |
Balance, September 30, 2023 | | 659,159,977 | | | $ | 306,561 | | | $ | 63,461 | | | $ | (420,722) | | | $ | (50,700) | | | $ | 108 | | | $ | (50,592) | |
See accompanying notes to condensed consolidated interim financial statements.
3
4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) (unaudited)
For the Nine Months Ended September 30, 2023 and 2022
(Amounts expressed in thousands of U.S. dollars except for share data)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Share Capital | | | | | | | | | | |
| | Shares | | Amount | | Additional Paid-In Capital | | Deficit | | Total 4Front Ventures Corp. Shareholders' Equity (Deficit) | | Non-Controlling Interest | | Total Shareholders' Equity (Deficit) |
Balance, December 31, 2021 | | 594,181,604 | | | $ | 274,120 | | | $ | 52,197 | | | $ | (288,857) | | | $ | 37,460 | | | $ | 72 | | | $ | 37,532 | |
Shares issued for NECC pursuant to acquisition | | 28,571,428 | | | 18,200 | | | — | | | — | | | 18,200 | | | — | | | 18,200 | |
Share-based compensation | | — | | | — | | | 1,038 | | | — | | | 1,038 | | | — | | | 1,038 | |
Conversion of notes to equity | | 6,235,512 | | | 3,122 | | | — | | | — | | | 3,122 | | | — | | | 3,122 | |
Shares issued with exercise of warrants | | 88,659 | | | 50 | | | — | | | — | | | 50 | | | — | | | 50 | |
Net loss | | — | | | — | | | — | | | (5,899) | | | (5,899) | | | 5 | | | (5,894) | |
Balance, March 31, 2022 | | 629,077,203 | | | $ | 295,492 | | | $ | 53,235 | | | $ | (294,756) | | | $ | 53,971 | | | $ | 77 | | | $ | 54,048 | |
Shares issued for Island pursuant to acquisition | | 8,783,716 | | | 6,245 | | | — | | | — | | | 6,245 | | | — | | | 6,245 | |
Warrants issued for Island pursuant to acquisition | | — | | | 732 | | | — | | | — | | | 732 | | | — | | | 732 | |
Share-based compensation | | — | | | — | | | 390 | | | — | | | 390 | | | — | | | 390 | |
Shares issued with exercise of stock options | | 51,975 | | | 33 | | | — | | | — | | | 33 | | | — | | | 33 | |
Net loss | | — | | | — | | | — | | | (6,551) | | | (6,551) | | | 5 | | | (6,546) | |
Balance, June 30, 2022 | | 637,912,894 | | | $ | 302,502 | | | $ | 53,625 | | | $ | (301,307) | | | $ | 54,820 | | | $ | 82 | | | $ | 54,902 | |
Shares issued for Bloom pursuant to acquisition | | 3,750,000 | | | $ | 2,100 | | | $ | — | | | $ | — | | | $ | 2,100 | | | $ | — | | | $ | 2,100 | |
Share-based compensation | | — | | | $ | — | | | $ | 862 | | | $ | — | | | $ | 862 | | | $ | — | | | $ | 862 | |
Shares issued with exercise of stock options | | | | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | — | |
Net loss | | — | | | $ | — | | | $ | — | | | $ | (8,606) | | | $ | (8,606) | | | $ | 5 | | | $ | (8,601) | |
Balance, September 30, 2022 | | 641,662,894 | | | $ | 304,602 | | | $ | 54,487 | | | $ | (309,913) | | | $ | 49,176 | | | $ | 87 | | | $ | 49,263 | |
See accompanying notes to condensed consolidated interim financial statements.
4
4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (unaudited)
For the Nine Months Ended September 30, 2023 and 2022
(Amounts expressed in thousands of U.S. dollars)
| | | | | | | | | | | | | | |
| | Nine Months Ended September 30, |
| | 2023 | | 2022 |
CASH FLOWS FROM OPERATING ACTIVITIES | | | | |
Net loss from continuing operations | | $ | (39,563) | | | $ | (9,592) | |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | |
Depreciation and amortization | | 4,222 | | | 4,594 | |
Equity based compensation | | 4,912 | | | 2,291 | |
Change in fair value of derivative liability | | 11,931 | | | (3,494) | |
Accretion of lease liability | | 4,502 | | | 57 | |
| | | | |
| | | | |
| | | | |
Loss on disposal | | 160 | | | — | |
Change in contingent consideration payable | | — | | | (2,393) | |
Accretion of debt discount | | 355 | | | — | |
Accrued interest on convertible debenture and interest | | 678 | | | 872 | |
Accrued interest on notes payable | | 7,261 | | | 6,483 | |
Interest accrued - lease receivable | | 1,040 | | | 671 | |
Interest on construction liability | | — | | | 1,143 | |
Deferred taxes | | 1,196 | | | (965) | |
| | | | |
| | | | |
Changes in operating assets and liabilities: | | | | |
Accounts receivable, net | | 1,240 | | | (3,777) | |
Other receivables | | (129) | | | 276 | |
Prepaid expenses and other assets | | (824) | | | 28 | |
Inventory | | 1,726 | | | (6,051) | |
Accounts payable | | 1,869 | | | 6,525 | |
Accrued expenses and other current liabilities | | (143) | | | 4,229 | |
| | | | |
Taxes payable | | 1,962 | | | 8,643 | |
Deposits | | 977 | | | — | |
Net cash provided by continuing operating activities | | 3,372 | | | 9,540 | |
Net cash used in discontinued operating activities | | (7,443) | | | (11,700) | |
NET CASH USED IN OPERATING ACTIVITIES | | (4,071) | | | (2,160) | |
CASH FLOWS FROM INVESTING ACTIVITIES | | | | |
Cash paid for asset acquisitions and business combinations, net of cash received | | (250) | | | (24,998) | |
Proceeds from note receivable | | — | | | 109 | |
| | | | |
Purchases of property and equipment | | (267) | | | (1,683) | |
Net cash used in continuing investing activities | | (517) | | | (26,572) | |
Net cash used in discontinued investing activities | | (284) | | | (400) | |
NET CASH USED IN INVESTING ACTIVITIES | | (801) | | | (26,972) | |
CASH FLOWS FROM FINANCING ACTIVITIES | | | | |
Payment of contingent consideration | | — | | | (412) | |
Proceeds from issuance of construction financing liability | | — | | | 16,000 | |
Payment on construction financing liability | | — | | | (1,143) | |
Notes payable issued | | — | | | 3,000 | |
Proceeds from the exercise of warrants | | — | | | 50 | |
Proceeds from the exercise of stock options | | — | | | 33 | |
| | | | |
Repayments of notes payable | | (6,634) | | | (5,871) | |
Net cash (used in) provided by continuing financing activities | | (6,634) | | | 11,657 | |
Net cash (used in) provided by discontinued financing activities | | — | | | — | |
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES | | (6,634) | | | 11,657 | |
See accompanying notes to condensed consolidated interim financial statements.
5
4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (unaudited)
For the Nine Months Ended September 30, 2023 and 2022
(Amounts expressed in thousands of U.S. dollars)
| | | | | | | | | | | | | | |
NET DECREASE IN CASH | | (11,506) | | | (17,475) | |
CASH, BEGINNING OF PERIOD | | 14,271 | | | 22,435 | |
CASH, END OF PERIOD | | $ | 2,765 | | | $ | 4,960 | |
| | | | | | | | | | | | | | |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | | | | |
Non-cash investing and financing activities: | | | | |
Issuance of warrants for debt amendments | | $ | 4,165 | | | $ | — | |
Exchange of convertible debt to equity | | $ | — | | | $ | 3,122 | |
Issuance of equity for business combinations | | $ | — | | | $ | 24,445 | |
Issuance of warrants for business acquisition | | $ | — | | | $ | 732 | |
Issuance of equity for asset acquisition | | $ | 447 | | | $ | 2,100 | |
Shares issued to settle payables | | $ | 650 | | | $ | — | |
Termination of right-of-use assets and lease liabilities | | $ | — | | | $ | 2,020 | |
Transfers of property and equipment from assets related to discontinued operations to continuing operations | | $ | 5,498 | | | $ | — | |
See accompanying notes to condensed consolidated interim financial statements.
6
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Note 1: NATURE OF OPERATIONS
4Front Ventures Corp. (“4Front” or the “Company”) exists pursuant to the provisions of the British Columbia Corporations Act. The Company operates the business through two segments: THC Cannabis and CBD Wellness. As of September 30, 2023, the Company's THC Cannabis segment consists of six dispensaries and four production and cultivation facilities across Illinois, Michigan, and Massachusetts. Also, as part of its THC Cannabis segment, the Company leases real estate and sells equipment, supplies, and intellectual property to cannabis producers in the state of Washington. The Company’s CBD Wellness segment sells non-THC hemp derived products across the United States.
The unaudited condensed consolidated interim financial statements include the accounts of 4Front and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The Company has prepared these statements pursuant to the rules and regulations of the United States Securities and Exchange Commission (SEC) and U.S. GAAP. Certain information related to the organization, significant accounting policies, and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted.
In the opinion of management, the financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. Operating results for interim periods are not necessarily indicative of results you can expect for a full year. These financials should be read in conjunction with our audited consolidated financial statements and notes thereto appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
Going Concern
As of September 30, 2023, the Company had cash of $2.8 million and working capital deficit of $64.2 million. The Company incurred net losses from continuing operations of $26.4 million and $4.0 million for the three months ended September 30, 2023 and 2022, respectively, and $39.6 million and $9.6 million for the nine months ended September 30, 2023 and 2022, respectively. The conditions described above raise substantial doubt with respect to the Company’s ability to meet its obligations for at least one year from the issuance of these consolidated financial statements, and therefore, to continue as a going concern.
The Company plans to continue to fund its operations through cash generated from sales and is deploying its capital reserves to acquire and develop assets capable of producing additional revenues and earnings over both the immediate and near term. Capital reserves are being utilized for capital expenditures and improvements in existing facilities, product development and marketing, as well as customer, supplier and investor and industry relations. The Company has raised capital as needed, however there is no guarantee the Company will be able to continue to raise funds in the same manner it has historically.
Reclassifications
Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications did not affect net loss, revenues and stockholders’ equity.
Under ASC Subtopic 205-20, “Presentation of Financial Statements - Discontinued Operations” (“ASC Subtopic 205-20”), a component of an entity that is classified as discontinued operations is presented separately from continuing operations in the consolidated statements of operations and the consolidated statements of cash flows for all periods presented. All assets and liabilities related to such discontinued operations are presented separately in the consolidated balance sheets for all periods presented. Accordingly, the presentation of prior period balances may not agree to prior issued financial statements. See Note 16 for further information on discontinued operations.
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Management's Estimates and Assumptions
The preparation of the Company’s financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. We cannot predict what future laws and regulations might be passed that could have a material effect on our results of operations. We assess the impact of significant changes in laws and regulations on a regular basis and update the assumptions and estimates used to prepare our financial statements when we deem it necessary. Actual results may differ from these estimates. The most critical and subjective areas are discussed in detail in the notes in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. There have been no changes to the Company's accounting policies since the Annual Report.
Discontinued Operations
A component of an entity is identified as operations and cash flows that can be clearly distinguished, operationally and financially, from the rest of the entity. Under ASC Subtopic 205-20, “Presentation of Financial Statements - Discontinued Operations” (“ASC Subtopic 205-20”), a discontinued operation that is being disposed of other than by sale is considered held and used until the date of abandonment at which time it meets the criteria to be presented as discontinued operations. As of September 30, 2023, the Company's California operation, the component, was considered abandoned and are presented as discontinued operations separately from continuing operations in the consolidated balance sheets, consolidated statements of operations and the consolidated statements of cash flows for all periods presented.
New Accounting Pronouncements
Accounting Standard Updates Issued but Not Yet Adopted
In June 2022, the FASB issued ASU 2022-03, "Fair Value Measurements - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (Topic 820)". ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. It also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. For public business entities, the ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted and the amendments in the ASU should be applied prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. The Company is currently assessing the impact of adopting ASU 2022-03 on the consolidated financial statements.
In March 2023, the FASB issued ASU 2023-01, “Leases (Topic 842) – Common Control Arrangements”, which require that leasehold improvements associated with common control leases be amortized by the lessee over the useful life of the leasehold improvements to the common control group (regardless of the lease term) as long as the lessee controls the use of the underlying asset. It also requires such leasehold improvements to be accounted for as a transfer between entities under common control through an adjustment to entity if, and when, the lessee no longer controls the use of the underlying asset. ASU 2023-01 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact of adopting ASU 2023-01 on the consolidated financial statements.
In July 2023, the FASB issued ASU 2023-03, “Presentation of Financial Statement (Topic 205), Income Statement - Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation - Stock Compensation (Topic 718)”, to amend various SEC paragraphs in the Accounting Standards Codification to reflect the issuance of SEC Staff Accounting Bulletin No. 120, among other things. The ASU does not provide any new guidance so there is no transition or effective date associated with it. The Company is currently assessing the impact of adopting ASU 2023-03 on the consolidated financial statements.
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
In October 2023, the FASB issued ASU 2023-06, "Disclosure Improvements," which incorporates certain existing or incremental disclosures and presentation requirements of SEC Regulations S-X and S-K into the FASB Accounting Standards Codification (the “Codification”). ASU 2023-06 is effective for the Company as of the effective date to remove the existing disclosure requirement from Regulations S-X and S-K. Early adoption is not permitted. The Company is currently assessing the impact of adopting ASU 2023-06 on the consolidated financial statements.
Note 2: INVENTORY
The Company’s inventories are summarized in the table below:
| | | | | | | | | | | | | | |
| | September 30, 2023 | | December 31, 2022 |
Raw materials - unharvested cannabis | | $ | 2,726 | | | $ | 2,431 | |
Raw materials - harvested and purchased cannabis | | 6,467 | | | 6,753 | |
Packaging and other non-finished goods | | 1,056 | | | 713 | |
Work in process - manufactured and purchased extracts | | 1,429 | | | 3,412 | |
Finished goods | | 5,484 | | | 5,579 | |
Total inventory | | $ | 17,162 | | | $ | 18,888 | |
Note 3: PROPERTY, PLANT, AND EQUIPMENT
Property, plant, and equipment and related depreciation are summarized in the table below:
| | | | | | | | | | | | | | |
| | September 30, 2023 | | December 31, 2022 |
Land | | $ | 774 | | | $ | 774 | |
Buildings & improvements | | 12,584 | | | 13,784 | |
Construction in process | | 2,285 | | | 82 | |
Furniture, equipment & other | | 17,025 | | | 8,963 | |
Leasehold improvements | | 20,133 | | | 19,544 | |
Total | | $ | 52,801 | | | $ | 43,147 | |
Less: accumulated depreciation | | (13,515) | | | (8,733) | |
Total property, plant, and equipment, net | | $ | 39,286 | | | $ | 34,414 | |
Depreciation expense related to continuing operations for the three months ended September 30, 2023 and 2022 was $0.8 million and $0.9 million, respectively, of which $0.6 million and $0.7 million, respectively, is included in cost of goods sold. Depreciation expense related to continuing operations for the nine months ended September 30, 2023 and 2022 was $2.3 million and $2.7 million, respectively, of which $1.8 million and $2.1 million, respectively, is included in cost of goods sold.
Unless specifically excluded in the LI Lending note, all property, plant, and equipment is secured by LI Lending as collateral on the LI Lending note (Note 8).
On October 27, 2022, the Company amended its lease agreement for the Company’s facility located in Matteson, Illinois by creating an option to increase the tenant improvement allowance for the facility between $15.0 million and $19.9 million. On November 10, 2022, the Company exercised its option and entered into a Second Amendment to Lease Agreement, increasing the tenant improvement allowance under the lease by $19.9 million; extending the term of the lease to 20 years after the amendment; increasing the base rent by $0.2 million per month (abated until April 1, 2023); and increasing the security deposit by $2.2 million, to be funded pro rata out of draws on the tenant improvement allowance.
Refer to Note 16 for discussion of assets related to the Company's operations in California classified as discontinued operations.
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Note 4: INTANGIBLE ASSETS AND GOODWILL
Intangible Assets
Intangible assets and related amortization are summarized in the table below:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Licenses | | Customer Relationships | | Non-Compete Agreements | | Know-How | | Tradenames and Trademarks | | Total |
Gross Carrying Amount, December 31, 2022 | | $ | 25,661 | | | $ | 2,900 | | | $ | 249 | | | $ | 9,700 | | | $ | 101 | | | $ | 38,611 | |
Impairment | | — | | | — | | | — | | | — | | | — | | | — | |
Gross Carrying Amount, September 30, 2023 and December 31, 2022 | | $ | 25,661 | | | $ | 2,900 | | | $ | 249 | | | $ | 9,700 | | | $ | 101 | | | $ | 38,611 | |
| | | | | | | | | | | | |
Accumulated Amortization, December 31, 2022 | | $ | — | | | $ | (2,393) | | | $ | (249) | | | $ | (6,628) | | | $ | (101) | | | $ | (9,371) | |
Amortization Expense | | — | | | (434) | | | — | | | (1,455) | | | — | | | (1,889) | |
Impairment | | — | | | — | | | — | | | — | | | — | | | — | |
Accumulated Amortization, September 30, 2023 | | $ | — | | | $ | (2,827) | | | $ | (249) | | | $ | (8,083) | | | $ | (101) | | | $ | (11,260) | |
Intangible Assets, Net at December 31, 2022 | | $ | 25,661 | | | $ | 507 | | | $ | — | | | $ | 3,072 | | | $ | — | | | $ | 29,240 | |
Intangible Assets, Net at September 30, 2023 | | $ | 25,661 | | | $ | 73 | | | $ | — | | | $ | 1,617 | | | $ | — | | | $ | 27,351 | |
During the nine months ended September 30, 2023, the Company entered into an agreement to acquire a dispensary license from Euphoria, LLC. Refer to Note 5 for further details on the transaction.
Goodwill
| | | | | | | | |
Balance, December 31, 2022 | | $ | 41,807 | |
Adjustment to Acquisitions | | — | |
Impairment | | — | |
Balance, September 30, 2023 | | $ | 41,807 | |
Impairment of Intangible Assets and Goodwill
Goodwill as of September 30, 2023 is related to the THC Cannabis segment in which there is no accumulated impairment within this segment. Goodwill related to the CBD Wellness segment has an accumulated impairment charge of $13.4 million, which represented the entire balance and occurred during the year ended December 31, 2020. As of September 30, 2023 and December 31, 2022, all goodwill and intangibles are attributable to the THC Cannabis segment.
Goodwill and infinite lived assets are assessed on an annual basis for impairment, or more frequently, if circumstances indicate an impairment to the carrying value may have occurred. As of September 30, 2023, the Company believes the carrying amounts of the long-lived assets, including finite-lived intangible assets (licenses), are recoverable and there were no events or circumstances that indicated impairment for any assets outside of California. However, if adverse events were to occur or circumstances were to change indicating the carrying amount of such assets may not be fully recoverable, the assets would be reviewed for impairment.
Refer to Note 16 for discussion of intangible assets and goodwill related to the Company's operations in California classified as discontinued operations.
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Note 5: ASSET ACQUISITIONS
Euphoria, LLC
On March 27, 2023, the Company entered into a Membership Interest Purchase Agreement to acquire 100% of the issued and outstanding equity interests in Euphoria, LLC ("Euphoria") for a total purchase price of $4.5 million to be paid in cash, promissory notes, and Class A Subordinate Voting Shares. Euphoria holds a conditional adult use dispensary license in the state of Illinois which shall convert to a state license upon regulatory approval. The transfer of the license is subject to regulatory approval. As of September 30, 2023, the Company has paid $0.3 million in cash and issued 2,308,952 Class A Subordinate Voting Shares valued at $0.4 million based on the closing stock price of the SVS on the issuance date. In certain events as defined in this agreement, such as, but not limited to the inability to obtain regulatory approval, all consideration paid by the Company to the sellers are refundable. The remaining consideration will be due upon regulatory approval at the closing date. In the event of termination by the Company under certain circumstances, the Company shall pay a breakup fee of $3.5 million to the sellers, less any portion of the purchase price already paid. Conversely, in the event of termination by the sellers under certain circumstances, the sellers shall pay a breakup fee of $3.5 million to the Company.
Note 6: DERIVATIVE LIABILITY
In November 2022, the warrants issued in connection with the November 2020 private placement had expired unexercised and, accordingly, the balance of derivative liabilities was nil as of December 31, 2022.
In connection with the amendment of the senior secured debt with LI Lending LLC in July 2023, the Company issued 100,358,824 warrants on August 10, 2023 wherein each warrant shall be exercisable into one (1) Subordinate Voting Share at an exercise price of $0.17 through May 1, 2026. If 4Front obtains a bona fide offer from a third party to refinance the loan within six months from the amendment date, the lender will have the option to match the proposed terms of the offer or keep the loan in force; upon exercise of either option, the lender's warrant coverage will be reduced to 30% of the loan balance divided by the exercise price as of the current maturity date. If 4Front obtains permitted secured debt senior to the loan up to $8 million, 75% of the warrants will become exercisable by cashless exercise. If 4Front obtains permitted secured debt senior to the loan in excess of $8 million (up to the $10 million maximum), 100% of the warrants will become exercisable by cashless exercise. The warrants met the criteria in ASC 480 due to the variability of the number of issuable shares, and are therefore classified as liabilities at fair value with changes being reported through the statement of operations. See Note 8 for further information on the July 2023 amendment.
The fair value of the warrants classified as liabilities was determined using the Black-Scholes simulation model based on Level 3 inputs on the fair value hierarchy. The following assumptions were used for the periods presented:
| | | | | | | | | | | | | | |
| | Issuance Date | | September 30, 2023 |
Share Price | | $ | 0.10 | | | $ | 0.25 | |
Exercise Price | | $ | 0.17 | | | $ | 0.17 | |
Expected Life | | 2.7 years | | 2.6 years |
Annualized Volatility | | 84.5 | % | | 88.8 | % |
Risk-Free Annual Interest Rate | | 4.5 | % | | 4.8 | % |
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
For the three and nine months ended September 30, 2023 and 2022, changes in fair value of the derivative liabilities measured on a recurring basis using significant unobservable inputs (Level 3) were as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 30, | | Nine Months Ended September 30, |
| | 2023 | | 2022 | | 2023 | | 2022 |
Balance, beginning of period | | $ | — | | | $ | 428 | | | $ | — | | | $ | 3,502 | |
Issuance of warrants | | 4,165 | | | — | | | 4,165 | | | — | |
Change in fair value of derivative liability | | 11,931 | | | (420) | | | 11,931 | | | (3,494) | |
Balance, end of period | | $ | 16,096 | | | $ | 8 | | | $ | 16,096 | | | $ | 8 | |
See Note 10 for warrants classified within equity.
Note 7: LEASES
New Lease Agreement
On August 23, 2023, the Company entered into a lease agreement for a third dispensary location in Illinois. Within five days of the agreement execution, the premise was available to the Company to begin leasehold improvements. The Company funded a security deposit with rent abated for the first nine calendar months following the rent commencement date. As of September 30, 2023, The Company recognized an initial right of use asset and lease liability of $1.2 million in connection with this agreement.
Modification of Lease Agreement
On July 7, 2023, the Company amended its lease agreement for the cultivation and production facility in Matteson, Illinois to apply a portion of the security deposit to pay one-half of the monthly base rent for the four month period through November 30, 2023; to defer payment of the $2.2 million increase in security deposit to be funded as draws on the tenant improvement allowance through November 30, 2023; and to make pro rata payments of such deferred payments equal to 1/12 of the aggregate amount, concurrently with monthly base rent installments, for the twelve month period commencing January 1, 2024. There was no modification to the lease accounting as a result of this amendment to the timing of payments of the refundable security deposit.
Discontinued Operations
During the fiscal quarter ended September 30, 2023, the Company ceased its cultivation and production operations in the state of California (together, the "California operations") as reported under the THC Cannabis segment. As a result, all prior year right-of-use assets and lease liabilities were reclassified as assets related to discontinued operations and liabilities related to discontinued operations, respectively in prior periods reflected. As of September 30, 2023, the right-of-use assets and lease liabilities related to the discontinued operations were written off.
The Company as a Lessor:
Lease income for operating and direct financing leases for the periods presented are as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | Nine Months Ended September 30, |
| 2023 | | 2022 | | 2023 | | 2022 |
Real estate income: | | | | | | | |
Operating leases | $ | 2,318 | | | $ | 2,424 | | | $ | 6,952 | | | $ | 6,952 | |
Direct financing leases | 574 | | | 641 | | | 1,795 | | | 2,029 | |
Total real estate income | $ | 2,892 | | | $ | 3,065 | | | $ | 8,747 | | | $ | 8,981 | |
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
The Company leases buildings in Olympia, Washington and Elk Grove, Illinois that are subleased or partly subleased to a third party. The subleases are classified as operating leases under ASC 842. The underlying assets are presented in the condensed consolidated balances sheets as follows:
| | | | | | | | | | | |
| September 30, 2023 | | December 31, 2022 |
Right-of-use assets | $ | 25,465 | | | $ | 26,133 | |
Current portion of lease liability | $ | 290 | | | $ | 295 | |
Long-term portion of lease liability | $ | 22,302 | | | $ | 22,078 | |
The Company also leases a building in Elma, Washington that is subleased to a third party. This sublease is classified as a finance lease. A reconciliation of the lease receivables is as follows:
| | | | | | | | | | | |
| September 30, 2023 | | December 31, 2022 |
Balance, beginning of period | $ | 9,421 | | | $ | 10,378 | |
Interest | 1,795 | | | 2,673 | |
Lease payments transferred to accounts receivable | (2,835) | | | (3,630) | |
Balance, end of period | 8,381 | | | 9,421 | |
Less current portion | (3,945) | | | (3,810) | |
Long-term lease receivables | $ | 4,436 | | | $ | 5,611 | |
Note 8: NOTES PAYABLE AND CONVERTIBLE NOTES
The Company’s notes payable and convertible notes are as follows:
| | | | | | | | | | | |
Terms | September 30, 2023 | | December 31, 2022 |
Secured promissory notes dated May 10, 2019, as subsequently amended, with a related party which mature on May 1, 2026 and bear interest at a rate of 16.5% per annum through May 1, 2024 and 12% per annum thereafter | $ | 46,827 | | | $ | 49,807 | |
Convertible promissory note dated October 6, 2021, which mature on October 6, 2024 and bear interest at a rate of 6% per annum (3) | 15,677 | | | 14,843 | |
| | | |
Unsecured convertible promissory note at $0.50 per share due December 18, 2023 at 12% per annum through May 2023 and 14% per annum through December 2023 (3) | 3,981 | | | 3,554 | |
Promissory note issued for the acquisition of NECC due January 7, 2023 at 10% per annum | — | | | 519 | |
Promissory note issued for the acquisition of Island due October 25, 2026 at 6% per annum | 10,880 | | | 10,431 | |
Secured promissory note due February 28, 2023 at 1.5% monthly interest for three months and 2% monthly interest for three months (1) | 2,561 | | | 3,230 | |
Unsecured promissory note due November 30, 2024, monthly interest payments at 12% per annum through September 2023 and 11% per annum through November 2024 (2) | 1,705 | | | 1,730 | |
| | | |
Various | 29 | | | 51 | |
Total Notes Payable and Convertible Notes | $ | 81,660 | | | $ | 84,165 | |
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
(1) The Company was in default of the secured promissory note as of September 30, 2023. Effective October 10, 2023, management has renegotiated the terms of the promissory note and extended the term of the lender note to January 1, 2024 in exchange for a loan extension fee of $0.1 million issued in warrants. Refer to Note 19 for further information.
(2) The Company entered into an amendment of this promissory note in September 2023 to reduce the interest rate to 11% and extend the maturity date to November 30, 2024.
(3) Refer to Note 19 for further information.
LI Lending LLC
On May 10, 2019, the Company entered into a loan agreement with LI Lending LLC, a related party, for $50.0 million, of which $43.0 million was drawn as of September 30, 2023 in two amounts: (i) $35.0 million bearing interest at a rate of 10.25% and (ii) $10.0 million bear interest at a rate of 12.25%. The loan matures on May 10, 2024 upon the Company shall pay an exit fee of 20% of the remaining principal balance.
In April 2020, the loan was amended to release certain assets previously held as collateral and to make principal prepayments totaling $2.0 million applied to the initial $35.0 million amount, decreasing the principal balance to $33.0 million. In December 2020, the loan was amended to increase the interest rate by 2.5% of which payments of the incremental interest were paid-in-kind until January 1, 2022. The Company was still required to make interest-only payments monthly of 10.25% on the initial $33.0 million and 12.25% on the final $10.0 million of the loan until January 1, 2022, when monthly interest rates were increased to 12.75% for the initial $35.0 million and 14.75% for the final $10.0 million for the remaining term.
In July 2023, the Company entered into the First Amendment to the loan agreement with LI Lending LLC to extend the maturity date of the related party loan to May 1, 2026, to reduce the interest rate to 12.0% per annum beginning May 1, 2024, and to expand the amount of third-party financings allowed under the loan agreement. As compensation for the amendment, the Company shall pay an extension fee of $0.5 million payable in cash on May 1, 2024. In addition, the Company issued 100,358,824 warrants on August 10, 2023 in accordance with this amendment. See Note 6 for further information regarding the fair value of the warrants. The amendment to the related party loan was not deemed to be a substantial modification under ASC Subtopic 470-50. As a result of the modification, the Company recorded an additional debt discount of $4.7 million related to the extension fee and the fair value of the warrants.
For the three months ended September 30, 2023 and 2022, the Company recognized accrued interest expense of $2.0 million and $2.5 million, respectively, on the related party loan and made $1.6 million and $2.2 million, respectively, in payments of principal and interest to the related party. For the nine months ended September 30, 2023 and 2022, the Company recognized accrued interest expense of $5.8 million and $5.8 million, respectively, on the related party loan and made $4.8 million and $4.7 million, respectively, in payments of principal and interest to the related party. See Note 13 for further discussion of this related party transaction.
October 2021 Convertible Note
On October 6, 2021, the Company entered into a convertible promissory note for $15.0 million that is exercisable into Class A Subordinate Voting Shares for $1.03 per share at any time at the option of the holder. The notes bear interest at 6% per annum and mature on October 6, 2024 upon which any remaining balance is payable in cash. All accrued and unpaid interest is payable in cash on an annual basis beginning on October 6, 2022. As of September 30, 2023, payments of principal and interest totaling $1.1 million have been made for this loan. As of September 30, 2023 and December 31, 2022, the unamortized discount balance related to the October 2021 Convertible Note was $0.2 million and $0.4 million, respectively, with a remaining amortization period of 1.00 year and 1.75 years, respectively. For the nine months ended September 30, 2023 and 2022, the Company recognized interest expense of $0.7 million and $0.3 million, respectively, and accretion of debt discount of $0.2 million and $0.1 million, respectively, related to the October 2021 Convertible Note.
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Note 9: SHAREHOLDERS' EQUITY
The Company has authorized an unlimited number of Class A Subordinate Voting Shares (“SVS”) and Class C Multiple Voting Shares (“MVS”), all with no par value.
All share classes are included within share capital in the consolidated statements of shareholders’ equity on an as- converted basis. Each share class is entitled to notice of and to attend any meeting of the shareholders, except a meeting of which only holders of another particular class of shares will have the right to vote. All share classes are entitled to receive dividends, as and when declared by the Company, on an as-converted basis, and no dividends will be declared by the Company on any individual class unless the Company simultaneously declares or pays dividends on all share classes. No subdivision or consolidation of any share class shall be made without simultaneously subdividing or consolidating all share classes in the same manner.
Voting shares activity for the periods presented is summarized as follows:
| | | | | | | | | | | | | | | | | | | | |
| | Class A Subordinate Voting Shares | | Class C Multiple Voting Shares | | Total |
Balance, December 31, 2022 | | 642,140,067 | | | 1,276,208 | | | 643,416,275 | |
Share capital issuances | | 15,743,702 | | | — | | | 15,743,702 | |
Balance, September 30, 2023 | | 657,883,769 | | | 1,276,208 | | | 659,159,977 | |
Class A Subordinate Voting Shares
Holders of Class A Subordinate Voting Shares are entitled to one vote in respect of each SVS.
Class C Multiple Voting Shares
Holders of Class C Multiple Voting Shares are entitled to 800 votes in respect of each MVS. One MVS can convert to one SVS but are not convertible until the aggregate number of MVS held by the Initial Holders (being the MVS holders on their initial issuance) are reduced to a number which is less than 50% of the aggregate number of MVS held by the Initial Holders on the date of completion of the business combination with Cannex.
| | | | | | | | |
Series | | September 30, 2023 |
Class A - Subordinate Voting Shares | | 657,883,769 | |
Class C - Multiple Voting Shares | | 1,276,208 | |
Total shares outstanding | | 659,159,977 | |
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Note 10: WARRANTS
A reconciliation of the beginning and ending balance of share purchase warrants outstanding is as follows:
| | | | | | | | | | | | | | |
| | Number of Warrants | | Weight-Average Exercise Price |
Balance, December 31, 2022 | | 6,352,278 | | | $ | 0.82 | |
Issued | | 1,375,000 | | | $ | 0.13 | |
| | | | |
Expired | | (2,227,303) | | | $ | 0.67 | |
Balance, September 30, 2023 | | 5,499,975 | | | $ | 0.70 | |
As of September 30, 2023, the Company had the following warrants outstanding:
| | | | | | | | | | | | | | |
Warrants Outstanding | | Exercise Price | | Expiration Date |
2,999,975 | | | $ | 1.00 | | | April 13, 2024 |
625,000 | | * | C$ | 0.80 | | | October 6, 2024 |
500,000 | | * | C$ | 0.80 | | | October 6, 2025 |
625,000 | | | C$ | 0.23 | | | May 10, 2027 |
750,000 | | | $ | 0.10 | | | September 1, 2027 |
5,499,975 | | | | | |
*Represents warrants that were exercisable as of September 30, 2023.
Refer to Note 6 for warrants classified as liability.
Note 11: SHARE-BASED COMPENSATION
The Company adopted two equity incentive plans where the Company may grant Class A stock options. Under the terms of the plans, the maximum number of stock options which may be granted are a total of 10% of the number of shares outstanding assuming conversion of all shares to SVS. The exercise price for stock options issued under the plans will be set by the Compensation Committee of the Board of Directors but will not be less than 100% of the fair market value of the Company’s shares on the grant date. Stock options have a maximum term of 10 years from the date of grant. Stock options vest at the discretion of the Board.
As of September 30, 2023, the Company had 26,943,098 options exercisable and 84,870,266 options outstanding, with exercise prices ranging from C$0.10 to C$1.63. The following table summarizes the Company’s stock option activity and related information:
| | | | | | | | | | | | | | | | | | | | |
| | Number of Options | | Weighted Average Price CAD$ | | Weighted Average Years |
Balance, December 31, 2022 | | 75,626,960 | | | $ | 0.86 | | | 3.46 |
Granted | | 60,724,666 | | | $ | 0.20 | | | 3.42 |
| | | | | | |
Forfeited/Expired | | (51,481,360) | | | $ | 0.83 | | | — | |
Balance, September 30, 2023 | | 84,870,266 | | | $ | 0.38 | | | 4.52 |
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
During the three months ended September 30, 2023 and 2022, the Company recognized share-based compensation of $2.6 million and $0.9 million, respectively. During the nine months ended September 30, 2023 and 2022, the Company recognized share-based compensation of $3.9 million and $2.3 million, respectively. In determining the amount of share-based compensation during the periods ended September 30, 2023 and 2022, the Company used the Black-Scholes option pricing model to establish the fair value of options granted with the following key assumptions:
| | | | | | | | | | | |
| Nine Months Ended September 30, |
| 2023 | | 2022 |
Risk-Free Interest Rate | 4.02 | % | | 3.62 | % |
Expected Life | 3.42 years | | 3.50 years |
Expected Annualized Volatility | 86.62 | % | | 89.83 | % |
Forfeiture rate | — | % | | — | % |
Expected Dividend Yield | — | % | | — | % |
Restricted Share Units
On July 27, 2023, the Company issued a total of 9,853,830 restricted share units ("RSUs"), at a deemed issue price of C$0.165 based on the closing price of its Subordinate Voting Shares, to certain officers and employees of the Company in payment of fiscal year-end 2022 bonus entitlements. The RSUs are fully vested as of the grant date and expire upon the earlier of 18 months following the grant date or the occurrence of certain events. As of September 30, 2023, the Company recognized share-based compensation of $1.2 million for these fully vested RSU grants.
Note 12: INCOME TAXES
The following table summarizes the Company's income tax expense:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | For the Three Months Ended September 30, | | For the Nine Months Ended September 30, |
| | 2023 | | 2022 | | 2023 | | 2022 |
Net loss from continuing operations before income taxes | | $ | (30,627) | | | $ | (669) | | | $ | (38,745) | | | $ | 209 | |
Income tax benefit (expense) | | $ | 4,199 | | | $ | (3,321) | | | $ | (818) | | | $ | (9,801) | |
The Company has computed its provision for income taxes under the discrete method which treats the year-to-date period as if it were the annual period and determines the income tax expense or benefit on that basis. The discrete method is applied when application of the estimated annual effective tax rate is impractical because it is not possible to reliably estimate the annual effective tax rate. At this time, there is a high degree of uncertainty in estimating the Company’s annual pre-tax income and significant non-deductible expenses so the Company cannot reliably estimate the annual effective tax rate.
Due to its cannabis operations, the Company is subject to the limitations of the U.S. Internal Revenue Code (“IRC”) Section 280E under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. Therefore, the effective tax rate can be highly variable and may not necessarily correlate with pre-tax income and provides for effective tax rates that are well in excess of statutory tax rates.
The Company files income tax returns in the U.S. and various state jurisdictions and is subject to examination of its income tax returns by tax authorities in these jurisdictions who may challenge any item on these returns. The corporate statute of limitations for these jurisdictions remains open for the 2019 tax year to the present. Prior to July 31, 2019, the Company was treated as a partnership for income tax purposes and tax income and losses generated from operations were passed through to the Company’s individual members.
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Note 13: RELATED PARTIES
LI Lending LLC
Linchpin Investors LLC (“Linchpin”), a subsidiary of the Company, and LI Lending LLC (“LI Lending”) entered into a Construction Loan Agreement dated May 10, 2019, as amended, whereby Linchpin received an up-to $50.0 million loan from LI Lending, of which $43.0 million was drawn as of September 30, 2023. Mr. Gontmakher, the CEO of the Company, and Roman Tkachenko, a director of the Company, each hold a 14.28% ownership interest in LI Lending. $51.6 million of the loan advanced includes the notes payable and accrued interest less debt discount of $4.7 million that was outstanding as of September 30, 2023. Of the $46.8 million outstanding at September 30, 2023, $8.0 million represents interest accrued through September 30, 2023. See Note 8 for details on the outstanding note payable.
In July 2023, the related party loan was amended wherein while the debt is outstanding, if the Company unilaterally removes Mr. Gontmakher as its Chief Executive Officer or Karl Chowscano as its President without either cause or lender consent, the maturity date of the loan will be accelerated to the date that is 30 days after the first unilateral removal. In addition, the exit fee of $9.0 million was replaced with deferred interest of $9.2 million which will be added to the principal of the promissory note on May 1, 2024, for a total payable at maturity of $51.7 million. Refer to Note 8 for additional amendment terms.
Note 14: CONTINGENCIES
(a) Cannabis Industry
While marijuana is legal under the laws of several U.S. states (with varying restrictions), the United States Federal Controlled Substances Act classifies all “marijuana” as a Schedule I drug, whether for medical or recreational use. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, there is an inherent risk related to the federal government’s position on cannabis. There is additional risk associated with the Company’s business in cannabis that third-party service providers could suspend or withdraw services and regulatory bodies could impose certain restrictions on the issuer’s ability to operate in the U.S. As of September 30, 2023, Company has not estimated a potential liability related to the possible enforcement of laws against the medical cannabis industry.
(b) Legal Matters
From time to time, the Company may be involved in certain disputes arising in the ordinary course of business. Such disputes, taken in the aggregate, are not expected to have a material adverse effect on the Company. There are also no proceedings in which any of the Company’s directors, officers, or affiliates is an adverse party or has a material interest adverse to the Company’s interest.
On January 26, 2022, Savills, Inc. sued the Company in the U.S. District Court for the Southern District of New York. That lawsuit alleged the Company had breached an alleged agreement with Savills under which the Company was allegedly required to pay Savills a percentage of savings realized under certain incentive programs offered in some jurisdictions, which Savills would assist the Company in obtaining. Savills claimed damages of approximately $19.4 million in connection with its claim that it obtained benefits for the Company allegedly valued at over $129.0 million. The Company denied these allegations, denied the Company had obtained such benefits, disputed Savills’ characterization of the facts, and denied liability. The Company filed a counterclaim against Savills alleging breach of contract by Savills. On August 3, 2022, the parties reached a confidential settlement in principle and agreed to dismissal of all claims, which was finalized on September 12, 2022 and required the Company to pay $0.25 million in five monthly installments beginning in October 2022. In addition to this initial payment, there is a portion of the settlement that is contingent on future tax savings. As of September 30, 2023, this additional contingent amount is not reasonably estimable.
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
On May 9, 2023, Florival LLC (“Florival”) sued the Company in the California Superior Court for the County of Santa Cruz. The lawsuit alleged the Company had breached an agreement with Florival under which Company subsidiary Island Global Holdings, Inc. (“Island”) agreed to purchase the membership interests of licensed cannabis cultivator Gold Coast Gardens, LLC. Florival claimed damages of $0.85 million. The Company denied it had any direct liability under the agreement, which was executed two years before the Company’s acquisition of Island and asserted an unclean hands defense on behalf of both the Company and Island based on Florival’s inequitable conduct during the litigation. On November 7, 2023, the court entered summary judgment against the Company and Island. The Company and Island intends to appeal the decision. Management has accrued $0.85 million related to this matter as of September 30, 2023.
On September 14, 2023, Teichman Enterprises, Inc. (“Teichman”) sued Company subsidiary 4Front California Capital Holdings, Inc. (“4Front CA”) in the California Superior Court for the County of Los Angeles. The lawsuit alleged 4Front CA had breached a lease with Teichman for 4Front CA’s facility in Commerce, California by failing to pay rent due under the lease. Teichman sought possession of the property and damages of $0.6 million. 4Front CA denied the allegations, but vacated the facility. Trial is set for January 2024. Management has accrued $0.6 million related to this matter as of September 30, 2023.
On September 29, 2023, Teichman Enterprises, Inc. sued 4Front CA and the Company in the Superior Court for the County of Los Angeles. The lawsuit alleged the Company had breached a lease agreement with Teichman under which the Company entered into a 10 year lease commitment ending on January 31, 2029, and that the Company breached its guarantee of the lease. Teichman has alleged total rent owed under the lease agreement is $13.4 million in addition to a license fee of $1.0 million and additional damages. Total damages sought from Teichman under the lease contracts is $15.5 million. 4Front CA and the Company denied the allegations in the compliant, and denied that Teichman was entitled to the full amount of damages claimed due to Teichman's obligation to mitigate. Based on management's review of case, the Company has accrued $2.0 million associated with this legal liability as of September 30, 2023.
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
Note 15: FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT
The fair value of the Company’s cash, accounts receivable, other receivables, accounts payable and accrued expenses approximates carrying value due to their short-term nature. The Company’s lease receivables, long term accounts payable and construction finance liability, convertible notes payable, and notes payable approximate fair value due to the instruments bearing market rates of interest. These measurements were identified as Level 1 measurements, due to the proximity of fair value to carrying values. The fair value of stock options granted were estimated based on a Black-Scholes model. The estimated fair value of the derivative liabilities, which represent warrants classified as liabilities, represent Level 3 measurements.
There were no transfers between fair value levels for the three and nine months ended September 30, 2023 and the year ended December 31, 2022.
(a) Financial Risk Management
The Company is exposed in varying degrees to a variety of financial instruments related risks. The Company's board of directors mitigate these risks by assessing, monitoring and approving the Company’s risk management processes.
(b) Credit Risk
Credit risk is the risk of loss associated with counterparty’s inability to fulfill its payment obligations. The Company’s credit risk is primarily attributable to cash, accounts receivable, lease receivables, and other receivables. The risk to cash deposits is mitigated by holding these instruments with regulated financial institutions. Accounts receivable, lease receivables, and other receivables credit risk arises from the possibility that principal and interest due may become uncollectible. The Company mitigates this risk by managing and monitoring the underlying business relationships.
The Company maintains cash with federally insured financial institutions. As of September 30, 2023 and December 31, 2022, the Company exceeded federally insured limits by $0.1 million and $10.1 million, respectively. The Company has historically not experienced any losses in such accounts. As of September 30, 2023 and December 31, 2022, the Company held an immaterial amount of cash in a Canadian account that is denominated in C$.
As of September 30, 2023 and December 31, 2022, the maximum credit exposure related to the carrying amounts of accounts receivable, other receivable, and lease receivables was $12.8 million and $15.0 million, respectively.
(c) Liquidity Risk
The Company manages liquidity risk through the management of its capital structure. The Company’s approach to managing liquidity is to raise sufficient capital to settle obligations and liabilities when due. The Company has raised capital as needed, however there is no guarantee the company will be able to continue to raise funds in the same manor it has historically.
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
The Company has the following gross contractual obligations as of September 30, 2023, which are expected to be payable in the following respective periods:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Less than 1 year | | 1 to 3 years | | 3 to 5 years | | Greater than 5 years | | Total |
Accounts payable and accrued liabilities | | $ | 21,263 | | | $ | 977 | | | $ | — | | | $ | — | | | $ | 22,240 | |
Convertible notes, notes payable and accrued interest | | 8,248 | | | 62,532 | | | 10,880 | | | — | | | 81,660 | |
Construction finance liability | | — | | | 16,000 | | | — | | | — | | | 16,000 | |
Total | | $ | 29,511 | | | $ | 79,509 | | | $ | 10,880 | | | $ | — | | | $ | 119,900 | |
(d) Foreign Exchange Risk
The Company is exposed to exchange rate fluctuations between United States and Canadian dollars. The Company’s share price is denominated in Canadian dollars. If the Canadian dollar declines against the United States dollar, the United States dollar amounts available to fund the Company through the exercise of stock options or warrants will be reduced. The Company also has bank accounts with balances in Canadian dollars. The value of these bank balances if converted to U.S. dollars will fluctuate. While the Company maintains a head office in Canada where it incurs expenses primarily denominated in Canadian dollars, such expenses are a small portion of overall expenses incurred by the Company. The Company does not have a practice of trading derivatives and does not engage in “natural hedging” for funds held in Canada.
Note 16: DISCONTINUED OPERATIONS
During the fiscal quarter ended September 30, 2023, the Company ceased its cultivation and production operations in the state of California (together, the "California operations") as reported under the TCH Cannabis segment. The Company concluded that the abandonment of its California operations represented a strategic shift and thus all assets and liabilities to the operations within the state of California were classified as discontinued operations. Long-lived assets related to the California operations ceased to be used as of September 30, 2023 and thus considered disposed of other than by sale as of September 30, 2023. The assets associated with the California operations were measured at the lower of their carrying amount or fair value less costs to sell. During the three and nine months ended September 30, 2023, the Company recognized a loss on disposal of $12.7 million for the net carrying value of the assets as of the disposition date which was determined as the book value less direct costs to sell and an impairment charge of $12.9 million for the write-off of its intangible assets and goodwill. The Company does not have significant continuing involvement with the California operations outside of the contract liabilities of $2.3 million and the litigation matters disclosed in Note 14.
Revenue and expenses, gains or losses relating to the discontinuation of California operations were eliminated from profit or loss from the Company’s continuing operations and are shown as a single line item in the consolidated statements of operations for all periods presented.
4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)
The operating results of the discontinued operations are summarized as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 30, | | Nine Months Ended September 30, |
| | 2023 | | 2022 | | 2023 | | 2022 |
REVENUE | | | | | | | | |
Revenue from sale of goods | | $ | 1,566 | | | $ | 4,032 | | | $ | 9,033 | | | $ | 6,791 | |
Real estate income | | 260 | | | 342 | | | 411 | | | 342 | |
| | | | | | | | |
Total revenues | | 1,826 | | | 4,374 | | | 9,444 | | | 7,133 | |
Cost of goods sold | | (6,666) | | | (6,388) | | | (21,992) | | | (10,464) | |
Gross profit | | (4,840) | | | (2,014) | | | (12,548) | | | (3,331) | |
OPERATING EXPENSES | | | | | | | | |
Selling, general and administrative expenses | | 1,310 | | | 2,167 | | | 4,703 | | | 6,047 | |
Depreciation and amortization | | 42 | | | 161 | | | 189 | | | 516 | |
| | | | | | | | |
Transaction and restructuring related expenses | | 942 | | | — | | | 942 | | | 1,335 | |
Impairment of goodwill and intangible assets | | 12,856 | | | — | | | 12,856 | | | — | |
| | | | | | | | |
| | | | | | | | |
Total operating expenses | | 15,150 | | | 2,328 | | | 18,690 | | | 7,898 | |
Loss from operations | | (19,990) | | | (4,342) | | | (31,238) | | | (11,229) | |
Other income (expense) | | | | | | | | |
| | | | | | | | |
Interest expense | | — | | | (3) | | | (32) | | | (7) | |
Loss on disposal | | (12,747) | | | — | | | (12,747) | | | — | |
Other | | (2,930) | | | (266) | | | (1,371) | |